Despite its growing threat to global health, research aimed at tackling antimicrobial resistance (AMR) has been constrained for many years, most likely due to the rapid evolution of resistance in pathogens, regulatory and policy barriers, and high research and development (R&D) costs.
However, recent developments have led to a growing belief that viable solutions to this pressing global health issue may be within reach. Georgia Mann, senior associate, Withers & Rogers discusses.